# Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

> **NCT07416188** · PHASE1,PHASE2 · RECRUITING · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 40 (estimated)

## Conditions studied

- Recurrent Glioblastoma
- Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
- Relapsed Cancer
- Recurrent Tumor
- Glioblastoma Multiforme
- Recurring Glioblastoma
- Brain and Central Nervous System Tumors
- Glioma
- Glioblastomas
- Grade IV Astrocytoma
- GBM
- Recurrent Glioma (Glioblastoma Multiforme)
- High Grade Glioma
- Glioma, Malignant
- Brain Cancer

## Interventions

- **DRUG:** LMP744
- **PROCEDURE:** Conventional Surgery or Biopsy

## Key facts

- **NCT ID:** NCT07416188
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-21
- **Primary completion:** 2030-12-31
- **Final completion:** 2032-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07416188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07416188, "Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT07416188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*